Skip to content
Sign in

PBYI · NASDAQ

Puma Biotechnology (PBYI) Stock Price & Fundamentals

$320.35−0.44%−$1.40End-of-day price as of Oct 9, 2026

Puma Biotechnology (PBYI) closed at $320.35 on Oct 9, 2026, down 0.44% from the previous close of $321.75.

Share price, past year

1Y −4.93%

52-week range $307.21 – $345.43. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$320.35
Sep 30, 2026$312.29
Aug 31, 2026$334.91
Jul 31, 2026$333.40
Jun 30, 2026$319.00
May 29, 2026$325.15
Apr 30, 2026$327.51
Mar 31, 2026$332.93
Feb 27, 2026$324.47
Jan 30, 2026$338.84
Dec 31, 2025$333.50
Nov 28, 2025$332.61
Oct 31, 2025$335.13

Key statistics

Market cap
$16.37B
P/E (TTM)
616.1
EPS (TTM)
$0.52
Revenue (TTM)
$231.24M
Net income (TTM)
$26.72M
Shares outstanding
51.1M
Dividend yield
—
52-week range
$307.21 – $345.43

Puma Biotechnology's market cap is $16.37B, based on a share price of $320.35 and 51.1M shares outstanding as of Jun 30, 2026.

Financials

Puma Biotechnology reported revenue of $228.37M for fiscal 2025, down 0.91% from fiscal 2024.

Puma Biotechnology earned net income of $31.11M in fiscal 2025, a net margin of 13.6%.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Puma Biotechnology annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$228.37M−0.9%$31.11M13.6%$0.61$41.73M
FY2024ended Dec 31, 2024$230.47M−2.2%$30.28M13.1%$0.62$38.86M
FY2023ended Dec 31, 2023$235.64M+3.3%$21.59M9.2%$0.45$26.87M
FY2022ended Dec 31, 2022$228.03M−9.9%$2.00K0.0%$0.00−$15.83M
FY2021ended Dec 31, 2021$253.16M+12.5%−$29.13M−11.5%−$0.72$20.65M
FY2020ended Dec 31, 2020$225.11M−17.3%−$60.00M−26.7%−$1.52$727.00K
FY2019ended Dec 31, 2019$272.26M+8.5%−$75.60M−27.8%−$1.95$22.07M
FY2018ended Dec 31, 2018$250.99M+806.6%−$113.58M−45.3%−$2.99−$24.54M
FY2017ended Dec 31, 2017$27.69M—−$291.96M−1,054.6%−$7.85−$172.90M
Puma Biotechnology quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$56.50M$8.19M$0.16
Q1 FY2026ended Mar 31, 2026$44.81M−$3.75M−$0.07
Q4 FY2025ended Dec 31, 2025$75.45M$13.44M$0.26
Q3 FY2025ended Sep 30, 2025$54.48M$8.84M$0.17
Q2 FY2025ended Jun 30, 2025$52.44M$5.86M$0.12
Q1 FY2025ended Mar 31, 2025$46.01M$2.97M$0.06
Q4 FY2024ended Dec 31, 2024$59.08M$19.31M$0.40
Q3 FY2024ended Sep 30, 2024$80.54M$20.32M$0.41

Company profile

Name
Puma Biotechnology Inc
Ticker
PBYI
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
10880 Wilshire Blvd., Suite 1700, Los Angeles, CA
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001401667

Recent SEC filings

Frequently asked questions

What is Puma Biotechnology's stock price?

Puma Biotechnology (PBYI) closed at $320.35 on Oct 9, 2026, down 0.44% from the previous close of $321.75.

What is Puma Biotechnology's market cap?

Puma Biotechnology's market cap is $16.37B, based on a share price of $320.35 and 51.1M shares outstanding as of Jun 30, 2026.

How much revenue does Puma Biotechnology make?

Puma Biotechnology reported revenue of $228.37M for fiscal 2025, down 0.91% from fiscal 2024.

What is PBYI's P/E ratio?

Puma Biotechnology's price-to-earnings ratio is 616.1, based on trailing twelve-month diluted EPS of $0.52.

Does Puma Biotechnology pay a dividend?

Puma Biotechnology's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Puma Biotechnology Inc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures